Predictive Oncology (US:POAI)2025-08-14 11:00Financial Performance - The company reported a loss from continuing operations of approximately $2.0 million for Q2 2025, compared to a loss of $2.5 million in Q2 2024[1][10]. - Revenue for Q2 2025 was $2,682, a significant decrease from $67,255 in Q2 2024, primarily due to decreased sales of tumor-specific 3D models and kits[8][11]. - Basic and diluted loss per common share from continuing operations was $0.22 for Q2 2025, down from $0.53 in Q2 2024[8][11]. - Total stockholders' deficit increased to $1,653,400 as of June 30, 2025, compared to a deficit of $202,610 as of December 31, 2024[8][9]. Cash and Expenses - The company ended Q2 2025 with $506,078 in cash and cash equivalents, down from $611,822 as of December 31, 2024[8][9]. - General and administrative expenses increased by $50,481 to $1,875,655 in Q2 2025, compared to $1,825,174 in Q2 2024[8][11]. Market Expansion and Product Development - The company is preparing for an aggressive market expansion of its ChemoFx assay in the U.S. and a de novo launch in Europe, both anticipated in Q4 2025[3][4]. - The company has developed two unique 3D liver toxicity models for Labcorp, which can evaluate drug metabolism and liver toxicity[4]. - The company identified three promising candidates for repurposing from abandoned drugs, specifically Afuresertib, Alisertib, and Entinosta, for colon and breast tumor indications[4]. Financing Activities - A standby equity purchase agreement for up to $10 million was announced with YA II PN, LTD, managed by Yorkville Advisors Global, LP[4].